Author: Benner, Brooke; Carson, William E.
Title: Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer Cord-id: 7vuyt571 Document date: 2021_1_13
ID: 7vuyt571
Snippet: Bruton’s tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19). Recently, BTK inhibitors acalabrutinib and ibrutinib have been found to protect against pulmonary injury in a small group of patients infected with SARS-CoV-2. The high levels of pro-inflammatory cytokines found in the circulation of COVID-19 patients with severe lung disease suggest the involvement of the innate immune system in
Document: Bruton’s tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19). Recently, BTK inhibitors acalabrutinib and ibrutinib have been found to protect against pulmonary injury in a small group of patients infected with SARS-CoV-2. The high levels of pro-inflammatory cytokines found in the circulation of COVID-19 patients with severe lung disease suggest the involvement of the innate immune system in this process. Understanding the potential mechanism of action of BTK inhibition in SARS-CoV-2 is clearly of importance to determine how acalabrutinib, ibrutinib and possibly other BTK inhibitors may provide protection against lung injury.
Search related documents:
Co phrase search for related documents- lung injury and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- lung injury and macrophage response: 1, 2, 3, 4, 5, 6, 7, 8
- lung tissue and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8
- lung tissue and macrophage response: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date